SCHEMBL23778237

SCHEMBL23778237

CCN(C(=O)O)[C@H]1CCN(C2CCC(C#N)(c3cccc(Cl)c3)CC2)C1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.44
CCR5 P51681 3/20 0.40
KCNH2 Q12809 1/20 0.40
DPP4 P27487 1/20 0.38
DPP8 Q6V1X1 1/20 0.38
DPP9 Q86TI2 1/20 0.38
USP30 Q70CQ3 2/20 0.37
KDM2B Q8NHM5 1/20 0.37
UBE2M P61081 2/20 0.36
DCUN1D1 Q96GG9 2/20 0.36
CNR2 P34972 1/20 0.36
KDM1A O60341 1/20 0.36
HRH3 Q9Y5N1 2/20 0.36
MCHR1 Q99705 1/20 0.36
CCR2 P41597 1/20 0.35
CHRM4 P08173 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23778224 0.90 CYP2D6 (0.44) CYP2D6CCR5KCNH2USP30UBE2M
SCHEMBL23778261 0.90 CYP2D6 (0.53) CYP2D6CCR5KCNH2USP30KDM1A
SCHEMBL23778241 0.89 CYP2D6 (0.50) CYP2D6CCR5KCNH2USP30UBE2M
SCHEMBL23778327 0.89 CYP2D6 (0.50) CYP2D6CCR5KCNH2USP30UBE2M
SCHEMBL23778326 0.88 KMT2A (0.48) CYP2D6CCR5KCNH2UBE2MDCUN1D1
SCHEMBL23778377 0.83 CYP2D6 (0.58) CYP2D6CCR5KCNH2USP30KDM1A
SCHEMBL23778460 0.83 CYP2D6 (0.58) CYP2D6CCR5KCNH2USP30KDM1A
SCHEMBL23778293 0.81 USP30 (0.39) CYP2D6CCR5KCNH2DPP4USP30
SCHEMBL23778384 0.80 CYP2D6 (0.46) CYP2D6CCR5KCNH2USP30HRH3
SCHEMBL23778421 0.80 CCR5 (0.47) CYP2D6CCR5KCNH2USP30HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109996792-B Heterocyclic compounds having activity as modulators of muscarinic M1 and/or M4 receptors in the treatment of CNS diseases and pain 赫普泰雅治疗有限公司 2023-02-17 CN claimed
EP-3526207-B1 HETEROCYCLIC COMPOUNDS HAVING ACTIVITY AS MODULATORS OF MUSCARINIC M1 AND/OR M4 RECEPTORS IN THE TREATMENT OF CNS DISEASES AND PAINS. HEPTARES THERAPEUTICS LTD (GB) 2021-09-08 EP claimed